PairMap Revolutionizes Drug Discovery with Precise Energy Calculations, Reduces Costs, Errors

PairMap, a novel computational method developed in collaboration between Associate Professor Masahito Ohue from Institute of Science Tokyo (Science Tokyo) and Alivexis Inc., has revolutionized drug discovery by enabling precise energy calculations for complex compound interactions. This advancement addresses the longstanding challenge of predicting binding affinities between potential drugs and their targets, particularly when dealing with large chemical transformations or significant molecular rearrangements that traditional methods struggle to handle effectively.

PairMap introduces a systematic approach by creating intermediate compounds that form step-by-step pathways between two molecules, thereby minimizing calculation errors, improving convergence rates, and reducing computational costs. This method significantly outperforms conventional techniques in binding energy predictions for chemically similar compounds, with an impressive reduction in mean absolute error from 1.70 kcal/mol to 0.93 kcal/mol when compared to traditional methods.

The study’s findings are validated through comprehensive evaluations using benchmark datasets and align closely with experimental data, underscoring PairMap’s practical applications and potential for redefining drug discovery processes. Unlike traditional approaches that rely on threshold-based introduction of intermediates, PairMap exhaustively explores all possible pathways while incorporating thermodynamic cycles into its calculations to ensure high accuracy.

By addressing complex chemical transformations efficiently, PairMap empowers researchers to explore previously challenging chemical spaces, accelerating the development of more effective and targeted medications for diseases with limited therapeutic options. Its integration into existing drug discovery workflows promises to reduce costs and time-to-market for new drugs, while future developments aim to extend its application to cases involving significant charge changes.

Instituted in 2024 following a merger between Tokyo Medical and Dental University (TMDU) and Tokyo Institute of Technology (Tokyo Tech), Science Tokyo’s mission is “Advancing science and human wellbeing to create value for and with society.” This partnership exemplifies the potential for interdisciplinary collaboration to drive innovation, as evidenced by PairMap’s groundbreaking contributions to computational drug design.